Biogen Inc. (0R1B)
LSE
Closed
Oct 7, 2026
Day's Range
220.1352 wk Range
138.07Overview - 0R1B - Biogen Inc.
Key Statistics
Valuation
Enterprise Value
40.30B
Price / Book
‪1.75‬
EV / EBITDA
‪11.99‬
Profitability
Profit Margin
‪8.32%‬
Operating Margin
‪25.05%‬
Return on Assets
‪5.20%‬
Return on Equity
‪4.57%‬
Ownership
Float
147.21M
Held by Insiders
‪0.18%‬
Held by Institutions
‪99.50%‬
Price stats
Beta
‪0.17‬
Peers - 0R1B - Biogen Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on LSE.
- 0R1BLSEBiogen Inc.+39.19%52-week change—P/E (Trailing)‪8.32%‬Profit Margin
- SANLSESantander UK Plc Preferred Stock 10.375% Perpetual+98.91%52-week change0.38P/E (Trailing)‪19.73%‬Profit Margin
- 0QAHLSEMerck & Co., Inc.+46.92%52-week change63.23P/E (Trailing)‪5.33%‬Profit Margin
- 0R0TLSEAmgen Inc.+33.48%52-week change19.38P/E (Trailing)‪30.01%‬Profit Margin
- 0P6SLSEBayer AG+44.73%52-week change19.01P/E (Trailing)‪-6.17%‬Profit Margin
- OGNLSEOrigin Enterprises plc+98.92%52-week change10.07P/E (Trailing)‪2.20%‬Profit Margin
- BAYLSEBay Capital Plc+99.66%52-week change-2608.70P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - 0R1B - Biogen Inc.
About
Biogen Inc. is a global biotechnology company focused on discovering, developing, and commercializing therapies for serious neurological, neurodegenerative, and rare diseases. Headquartered in Cambridge, Massachusetts, Biogen concentrates its portfolio on conditions such as multiple sclerosis, spinal muscular atrophy,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
